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Molecular genetics of cystinuria: Mutation analysis of SLC3A1 and
evidence for another gene in the Type I (silent) phenotype.
Background. Cystinuria is a hereditary disorder that affects luminal
transport of cystine and dibasic amino acids in kidney and small intestine.
Three subtypes have been defined on the basis of urinary excretion of
cystine in obligate heterozygotes. Mutations in the SLC3A1 gene have
been associated with the Type I phenotype.
Methods. We investigated 20 cystinuria patients from Quebec (8 Type
I/I, 9 Type I/III and 3 Type II/N) for mutations in SLC3A1. DNA was
studied by Southern blotting and by the single strand conformation
polymorphism (SSCP) protocol to identify mutations. Expression of
mutations in Xenopus oocytes was performed to confirm the effect of
missense mutations on cystine uptake.
Results. Six novel mutations (2 large deletions, a 2 bp deletion and 3
single bp substitutions) were identified on the Type I allele. Four missense
mutations (T216M, S217R, R270L and I618M) were expressed in vitro; the
first three changes significantly decreased uptake.
Conclusions. Combined with our previous work, we have identified
15/16 mutations in SLC3A1 on Type I alleles in the eight Type I/I patients,
but only one SLC3A1 mutation on the nine Type I alleles of the Type I/III
patients. Therefore, we propose that the Type I phenotype could be
caused by mutations in other, as yet unidentified cystinuria genes.
Cystinuria is an autosomal recessive disorder of the
kidneys and intestine in which the luminal transport of
cystine and dibasic amino acids (ornithine, arginine, and
lysine) is defective [1]. The incidence of cystinuria varies
considerably worldwide, from 1/2500 in Israeli Jews of
Libyan origin to 1/15,000 in the United States [1]. The
incidence in Quebec is 1/7000, making it one of the most
common of the inherited disorders [2].
Three distinct phenotypes have been described for
cystinuria, based on the urinary excretion of cystine in
obligate heterozygotes: Type I (silent carriers); Type II
(marked elevation); and Type III (mild elevation) [2].
Initially it was postulated that these phenotypes were
caused by allelic variation at a single locus. However, since
increased cystine excretion was observed in the Type I/I
probands compared to Type I/III patients, a hypothesis of
genetic complementation between different loci was pro-
posed [3].
In 1993, Lee et al [4] isolated a human cDNA (D2H) that
induced uptake of cystine, dibasic and some neutral amino
acids when expressed in Xenopus laevis oocytes. The gene,
named SLC3A1 according to GDB nomenclature, was
mapped by somatic cell hybridization [4] and by fluores-
cence in situ hybridization (FISH) analysis [5] to human
chromosomal region 2p21; this region contained a cystin-
uria locus as determined by linkage analysis [6]. Mutations
in the SLC3A1 gene have been reported in cystinuria
families from Italy/Spain [7–9], Israel/USA [10], Japan [11]
and Canada [12]. All the mutations have been associated
with chromosomes linked to Type I cystinuria, suggesting
that the SLC3A1 gene is responsible for the Type I subtype
while other genes might be implicated in Types II and III.
Recent linkage data are supportive of this hypothesis. Type
III and probably Type II cystinuria have been reported to
link to a different chromosomal region, to band 19q13.1
[13–15].
Although over 20 different mutations in SLC3A1 have
been reported, there has been little overlap in the muta-
tions seen in different populations. The most common
mutation identified thus far, the M467T mutation, is par-
ticularly frequent in Mediterranean populations [8] but
quite rare in our Quebec population [12]. By contrast, we
reported four novel mutations in French Canadians that
have not been observed in other communities [12]. In this
report, we continue our molecular genetic analyses in 20
cystinuria patients identified primarily through the Quebec
Network of Genetic Medicine urinary screening program:
eight Type I/I, nine Type I/III and three Type II/N patients.
We report several additional novel mutations from Quebec,
as well as in vitro expression analysis of four missense
1 See Editorial by Chesney, p. 279.
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mutations. Furthermore, we suggest that the Type I phe-
notype is not exclusively associated with mutations in
SLC3A1; mutations in other as yet unidentified genes could
account for these “silent” carriers.
METHODS
Patients
Eighteen unrelated patients were identified by the Que-
bec Network of Genetic Medicine newborn urinary screen-
ing program. Two patients were identified after stone
formation. Patients were classified into cystinuria subtypes
on the basis of urinary excretion patterns of obligate
heterozygous parents, as previously described [3]. Eight
patients were classified as Type I/I probands, nine patients
as Type I/III, and three patients as Type II/N. Detailed
clinical information is reported in an accompanying manu-
script [16].
Mutation detection
DNA was isolated from blood as previously reported
[17]. The DNA was studied by Southern blotting to identify
large genomic rearrangements and by single strand confor-
mational polymorphism (SSCP) analysis of the coding
region and intronic boundaries to identify single base
substitutions and small insertions/deletions, as described
[12]. Southern analysis was carried out by digestion of 5 to
10 mg DNA with an appropriate restriction enzyme, fol-
lowed by electrophoresis on a 0.8% agarose gel. The DNA
was transferred onto a Nytran plus (Schleicher & Schuell)
membrane by Southern blotting. The pre-hybridization,
hybridization and washing procedures were performed in
accordance with the manufacturer’s protocol. The entire
SLC3A1 cDNA was radiolabeled with the multiprime
oligolabeling kit (Amersham) and used as a probe for
hybridization.
For SSCP analysis, intronic primer sequences were ob-
tained from characterization of SLC3A1 genomic clones
except for three sequences that were obtained from Bisceg-
lia et al [7]. Primers used for SSCP analysis are shown in
Table 1. The SLC3A1 genomic clones were isolated by
screening bacteriophage lambda genomic libraries with the
radiolabeled SLC3A1 cDNA as probe. The clones were
confirmed by Southern blotting, subcloned into appropriate
vectors, and sequenced across the intron-exon boundaries.
All polymerase chain reaction (PCR) products were first
run on 9% polyacrylamide gels to detect possible hetero-
duplexes due to small insertions or deletions. The PCR
products were then denatured and electrophoresed (7 to 10
W overnight at room temperature) on 6% acrylamide: 4%
glycerol gels for SSCP analysis. Any PCR products with
altered migration patterns were sequenced directly using a
USB Sequenase PCR sequencing kit. The sequence change
was confirmed by restriction digestion, using a new PCR
Table 1. Sequences of primers for amplification of SLC3A1 exons
Exon no. Primers sequence Primer Primer name Fragment size
1a GCC TTA CTG CAG GAA GGC AC (S) S 244 149 1 216d
TGG CTA TGG TGG CCG CGA TG (A) A321
1b GAG CAG ACC CCG GAT CCA GGC AG (S) S94 228
TGG CTA TGG TGG CCG CGA TG (A) A321
1c CAG TGG CTT CTG TGC TGG TG (S) S278 163
GGG CAT GTA CCT TTC AGA TCT C (A) I430110
2 CCT TTA ACT AAA ACA AAG TAG GG (S) I431253 277
CTC TCA AAC CTC ATC CCC TC (A) I610144
3 TTC TAA TAC AAT CTT TCC CTA GC (S) I611248 262
GTT CAA TCA CTA CAT ATC TGC C (A) I765159
4 GGG CAA TGA TCT TTA TTT CTG GG (S) I766268 257
GTG TTT TAA ATA AAT ACC TAA ACC TC (A) I891163
5 GTT GTG ATA ATA ACG TAG TTA ATG (S) I892254 227
CTG ATG ACA TTT TCA GAA AAG GC (A) I1011153
6 GAG GTT GTC TAC ATT CAT ATA GAG (S) I1012283 270
GGG ATA CAC TGC AGA TCA CAC (A) I1136162
7 CCC AGT CTT CTG ACA GGC C (S) I1137251 303
CTG GAC AGC AAA GGC AAC AG (A) I1332156
8 TTT CAG AAA ACT GTG TAT ACA GC (S) I1333251 271
TGA ATA CTT GGT TTT ATA GCT GTG (A) I1500152
9 TTT GAC ATA GAA TAC CCT TCG CT (S) I1501210 137
TGA TAC TTA CAT CAA CAT TCA CAG (A) I1617110
10a CAA ACA ATT CTT AGA ATC AAA CAC (S) I1618252 164 1 200e
TCC CTT GTC CAG AAA AAT GCC (A) A1929
10b CAT CGA CAG AAT CTT TAT CGT GG (S) S1764 216 1 281f
GCT CCT ATA AGC CAT AAT TTA C (A) A2260
Abbreviations are: (S), sense primer; (A), antisense primer.
a,b,c Exons 1 and 10 were analyzed in multiple segments (a, b, c) due to their large size
d BamHI digest; e TaqI digest; f AccI digest
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fragment, if the mutation created or obliterated a naturally-
occurring restriction site. Otherwise, an ACRS (artificially-
created restriction site) primer was used to create a restric-
tion site during PCR. Missense mutations were tested on 25
controls, with ethnic backgrounds similar to those of the
cases, to identify polymorphisms. The diagnostic tests for
mutations, by restriction digestion, are described in Table
2.
Expression of mutations in oocytes
Site-directed mutagenesis was used to recreate the mu-
tation in the cDNA for SLC3A1. Two unique restriction
sites in the SLC3A1-containing plasmid were used to
release a “cassette” of DNA containing the desired mu-
tagenesis site. Mutagenesis was performed as previously
described [18]. Briefly, primers flanking the unique sites
were used with internal sense and antisense primers, that
contained the desired single bp change, to generate two
PCR products; these products overlapped at the site of
mutagenesis. In the next round, these two PCR products
were used as template with very small quantities of the
flanking primers to generate one large mutagenized PCR
product. This product was subsequently digested at the
unique restriction sites and ligated into the original plasmid.
Fig. 1. Sequence analysis for proband 1440
(left panel) and control (right panel). PCR
amplification was performed using the primers
indicated in Table 2 and direct sequencing of
the PCR fragment revealed a 2 bp (TG)
deletion in proband 1440.
Table 2. Primers for amplification and strategies for mutation detection
Primer sequence Primer Location Fragment Mutation Detection
59-CAA ACA ATT CTT AGA ATC AAA CAC-39 (S) Intronic, bp 1618252
to 1618229 bp
364 1810delTG Heteroduplexa
59-TCC CTT GTC CAG AAA AAT GCC-39 (A) Exonic, bp 1909 to bp
1929
59-TTC TAA TAC AAT CTT TCC CTA GC-39 (S) Intronic, bp 611248
to bp 611226
262 C647T
(T216M)
1N1aIII
59-GTT CAA TCA CTA CAT ATC TGC C-39 (A) Intronic, bp 765138
to bp 765159
59-TTC TAA TAC AAT CTT TCC CTA GC-39 (S) Intronic, bp 611248
to bp 611-26
262 A649C
(S217R)
1Af1III
59-GTT CAA TCA CTA CAT ATC TGC C-39 (A) Intronic, bp 765138
to bp 765159
59-GGG CAA TGA TCT TTA TTT CTG GG-39 (S) Intronic, bp 766268
to bp 766246
257 G809T
(R270L)
1DdeI
59-GTG TTT TAA ATA AAT ACC TAA ACC TC-39 (A) Intronic, bp 891142
to bp 891163
59-GTT GTG ATA ATA ACG TAG TAA ATG-39 (S) Intronic, bp 892–54 to
bp 892231
227 G1011A
(P337P)
2MspI
59-CTG ATG ACA TTT TCA GAA AAG GC-39 (A) Intronic, bp 1011131
to bp 1011153
Abbreviations are: (S) sense primer; (A) antisense primer.
a Only if present in heterozygous form
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Vent polymerase (NEB) was used for mutagenesis to reduce
PCR errors. The replacement cassettes with the cloning sites
were sequenced to verify that no additional changes were
introduced by PCR.
In vitro transcription of the cDNA was performed using
T3 polymerase. Xenopus oocytes were defolliculated using
Ca-free solution (90 mM NaCl, 3 mM KCl, 0.82 mM MgSO4,
10 mM HEPES, pH 7.5) containing 1.5 mg/ml collagenase
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Fig. 2. Restriction digestion analysis of three
mutations. Fragments were amplified using
primers indicated in Table 2, digested with
appropriate restriction enzymes and analyzed by
gel electrophoresis. (A) AflIII digestion of
Family 782 and two controls (C) for diagnosis
of the A649C (S217R) mutation. The mutation
creates a AflIII site that cleaves the normal
fragment of 262 bp into 178 and 84 bp
fragments. (B) DdeI digestion of proband 1226,
her father, and two controls (C) for the G809T
(R270L) mutation. The mutant PCR fragment
contains an artificially-created DdeI site that
cleaves the normal fragment of 140 bp into 111
and 29 bp fragments. The 29 bp fragment is not
seen on this gel. (C) MspI digestion of proband
818, her parents and 1 control (C) for the
G1011A (P337P) mutation. The mutation
obliterates a MspI restriction site which
normally cleaves into 171 and 55 bp fragments
(the 55 bp fragment is not seen on this gel). In
the absence of this restriction site, the
uncleaved fragment of 226 bp is seen in the
proband and her father.
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(Boehringer Mannheim, Mannheim, Germany) for 45 min-
utes and injected the following day, either with 50 nl H2O
or with 50 nl H2O containing 10 ng cRNA of the SLC3A1
mutants. Injected oocytes were incubated at 18°C using
antibiotic Barth’s solution containing: 90 mM NaCl, 3 mM
KCl, 0.82 mM MgSO4, 0.41 mM CaCl2, 0.33 mM Ca(NO3)2,
10 mM HEPES, 5% horse serum, 2.5 mM Na pyruvate, and
50 mg/ml gentamicin, pH 7.5. Radioactive L-cystine uptake
experiments were performed at 30, 24 and six hours after
injection. Oocytes were incubated in groups of 10 to 12
oocytes for one hour in 0.75 mM ND96 solution (96 mM
NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM
HEPES, pH 7.5) plus 30 mM L-cystine (containing 1.0 mCi
14C-labeled cystine). After one hour, uptakes were stopped
by washing oocytes five times with ice-cold ND96 solution.
Individual oocytes were then solubilized in 250 ml 10% SDS
and counted.
RESULTS
Mutation identification
The entire coding region of SLC3A1 and the 39UTR up
to the poly-adenylation site were analyzed by SSCP and by
heteroduplex analysis in all 20 patients. Southern blotting
was also performed to identify genomic rearrangements.
Six novel mutations were identified: a 2 bp deletion, three
single base substitutions and two genomic rearrangements.
A 2 bp deletion (1810delTG) in exon 10 was found in a
homozygous state in proband 1440-1. The deletion re-
moved the dinucleotide TG following bp 1810 (Fig. 1) and
created a stop codon 11 bp downstream of the deletion.
The cystinuria subtype of this patient could not be assigned
by standard methodologies (urinary excretion pattern in
obligate heterozygous parents), since the parents were
unavailable. However, we assume that this patient is a Type
I/I proband due to the identification of SLC3A1 mutations
on both alleles. SLC3A1 mutations have not been reported
in any other subtype of cystinuria.
Three coding substitutions were identified in the het-
erozygous state in three Type I/I probands. Two of these
substitutions altered the amino acid sequence. The third
substitution was silent but it was likely to affect splicing
since it affected the last bp of the exon.
In proband 782-1 (Type I/I), we found an A to C
substitution at bp 649, which converts the serine codon to
an arginine codon (S217R) in exon 3. This mutation
created an AflIII restriction site that was used to confirm
the mutation in this family. Figure 2A shows that the
proband, his affected sister (782-2), their mother (782-3)
and the mother’s cystinuric brother (782-5) have additional
bands of 178 and 84 bp, and therefore carry the mutation in
the heterozygous state. AflIII restriction analysis was used
to screen 25 control Quebec individuals for this mutation;
all controls were negative. The other mutation in this family
was a 2 bp deletion (974delGA) previously reported [12]; it
was present in the father and the two cystinuric siblings.
We identified a G to T substitution at bp 809 in patient
1226-1 (Type I/I) that converted codon 270 from an
arginine to a leucine residue (R270L) in exon 4. Since this
mutation did not affect a restriction site, an artificially-
created restriction site for DdeI was generated by PCR and
used to confirm the presence of this mutation. Figure 2B
depicts the diagnosis of this mutation in the proband and
her father, showing an extra band of 111 bp. Testing of 25
control individuals did not identify this substitution. The
second mutation in this proband was the M467T mutation,
the most common SLC3A1 mutation in Spanish cystinuric
families. We had previously seen this mutation in another
Quebec cystinuria patient, proband 947-1 ( [12] and Table
3 below).
A single bp change, a G to A substitution at bp 1011 in
exon 5, was identified in proband 818-1 (Type I/I). This
change did not alter the proline codon (P337P). However,
we hypothesize that this mutation, situated in the last bp of
exon 5, is likely to affect splicing since the consensus
sequence for 59 splice sites indicates a strong preference for
a G in the last bp of the exon. Mutations in this position in
other genes have been shown to affect splicing [19–21].
Restriction digestion was used to confirm this substitution
in the patient (Fig. 2C); the patient and her father have an
extra band of 226 bp. Twenty-five control individuals from
Quebec were negative. The second mutation in this pro-
band (E483X) was previously reported [12].
Southern analysis identified two distinct genomic rear-
rangements in proband 936 (Type I/I) and her parents (Fig.
3). HindIII digestion revealed three absent bands (approx-
imate sizes 20 kb, 9 kb and 6 kb) in the proband, as well as
Table 3. Summary of phenotypes and SLC3A1 mutations in cystinuria
patients
Patient Phenotype SLC3A1 Mutations
780-1 I/I T216M/T216M
782-1 I/I 974delGAa/S217R
817-1 I/I 150011 G3Ta/dela,b
818-1 I/I E483Xa/P337P
885-1 I/I 150011 G3Ta/?c
936-1 I/I delb/delb
1226-1 I/I R270L/M467T
1440-1 I/I 1810delTG/1810delTG
947-1 I/III M467T/?
732-1 I/III ?/?
829-1 I/III ?/?
830-1 I/III ?/?
872-1 I/III ?/?
979-1 I/III ?/?
988-1 I/III ?/?
1326-1 I/III ?/?
1390-1 I/III ?/?
918-1 II/N ?/?
1245-3 II/N ?/?
1336-1 II/N ?/?
a Reported in Horsford et al [12]
b Each deletion (del) is a different genomic rearrangement
c ? Mutation unknown1
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three novel bands (approximate sizes 12 kb, 7 kb and 4.5
kb) that were not seen in controls. The 12 and 7 kb bands
were present in the mother and absent in the father, while
the 4.5 kb band was seen in the father and absent in the
mother. EcoRI-digested Southern blotting, analysis of poly-
morphisms C114A (G38G) and A1854G (I618M), and
characterization of exon-containing fragments in genomic
clones allowed us to predict that the deletion from the
mother extended from exon 2 to the end of the gene
(beyond exon 10), while the father’s deletion appeared to
involve exons 1 up to and including exon 7 (data not
shown).
The T216M mutation, first reported in an Italian patient
[7], was also identified by SSCP and sequencing in one of
our probands, Type I/I patient 780-1 (data not shown); it
was not seen in 25 control individuals. By contrast, the
I618M substitution is quite common in patients and control
individuals from Quebec, as well as in other populations,
suggesting that it is likely to be a benign polymorphism.
Expression analysis
The four missense mutations seen in our Quebec pro-
bands (T216M, S217R, R270L and I618M) were tested by
in vitro expression analysis in Xenopus laevis oocytes. Each
of these changes was re-created in the SLC3A1 cDNA by
site-directed mutagenesis. Oocytes were injected with in
vitro transcribed RNA and uptake measurements were
performed at 30 hours after injection. Uptake was signifi-
cantly decreased for the T216M and the R270L mutations
(P , 0 .01) to levels that were approximately 30% and 7%,
respectively, of control uptake (data not shown). Uptake at
an earlier time point (24 hours) confirmed the decreased
values for the T216M and the R270L mutations (22% and
6% of control, respectively) and suggests lower values for
the S217R mutation (Fig. 4A). An additional experiment
was performed at an earlier time point (6 hr) for the S217R
mutation; the uptake was strikingly reduced, particularly
after subtraction of the blank (21% of control uptake; Fig.
4B).
Uptake for the I618M substitution was similar to control
values, suggesting that it is not a deleterious mutation.
DISCUSSION
Table 3 summarizes the phenotypic classification and
mutational results for all 20 probands. Six novel mutations
are reported here. The two large genomic rearrangements
are null mutations that would likely obliterate SLC3A1
function. The 2 bp deletion occurs in the last exon and
results in a termination codon downstream. However, since
this protein would be lacking only 80 amino acids at the
Fig. 3. Southern analysis for proband 936 and
her parents. HindIII-digested DNA was
electrophoresed on 0.8% agarose gels,
transferred by Southern blotting and hybridized
with the radiolabeled full-length SLC3A1
cDNA (2.3 kb). The proband is missing several
bands (20 kb, 9 kb, and 6 kb), suggesting that a
large deletion is present on both alleles. The
proband has three new bands; the 12 kb and 7
kb bands were inherited from the mother while
the 4.5 kb band was inherited from the father.
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C-terminus, it is possible that it could retain some function.
Miyamoto et al [22] examined the activity of several
C-terminal truncation mutants in vitro and found that their
smallest deletion (from bp 1533 to the end of the C-
terminus) had some residual activity. The patient with the
2 bp deletion in the homozygous state reported her first
kidney stone in her twenties. This is somewhat later than
the age of the first stone in several of our other Type I/I
probands. The urinary excretion profiles and risk of neph-
rolithiasis in these patients is reported in the accompanying
manuscript [16].
Three missense mutations (T216M, S217R and R270L)
all affect amino acids that are conserved in rat and rabbit,
suggesting that they are critical for proper function. The
T216M mutation involves one of the six potential N-linked
glycosylation sites [4] (consensus NXS/T), while the S217R
mutation affects the next residue over from this same
glycosylation site. Expression analysis confirmed the re-
duced activity (approximately 25% on average, of control
uptake) of the T216M construct at 30 and 24 hours,
although its uptake activity was higher at four days (75% of
control; data not shown). It is possible that this mutation
alters cellular trafficking by virtue of its effect on glycosyl-
ation. Presumably, when studied at later time points in the
oocyte expression system, more molecules can reach the
membrane to facilitate cystine transport. A similar phe-
nomenon was observed for the S217R mutation; although
some effect on uptake was seen at 24 hours, a clear
reduction was seen at six hours. This hypothesis has also
been put forth by others for the M467T mutation [23].
The R270L mutation abolished transport to 7% of
control values. This is the lowest value reported thus far for
missense mutations in SLC3A1 expressed in vitro; only four
other naturally-occurring mutations [11, 23] have been
studied in this manner. Although there is some controversy
with respect to the structure of the SLC3A1 gene product
[24], both proposed models (with one or four transmem-
brane domains) depict this arginine residue in the luminal
domain, relatively close to the second glycosylation site at
residues 261-263 [9].
Fifteen out of 16 mutations have been identified in the
Type I/I probands (this report and [12]). The patients with
homozygous mutant genotypes (1810delTG/1810delTG
and T216M/T216M) could theoretically be hemizygous for
the reported mutation with a deletion on the second allele.
Since parents were unavailable, we could not confirm
homozygosity for the same mutation. In either scenario,
however, the patient would have two deleterious mutations
in SLC3A1. Many of the reported mutations are quite
deleterious: three genomic rearrangements, probably the
two splice mutations, one nonsense mutation, and two
expressed mutations (T216M and R270L) with extremely
low activity. Since it has been postulated that the SLC3A1
gene encodes an activator of cystine transport, rather than
the transporter itself [4], a severe reduction in activator
protein might be required to reduce cystine transport.
Compatible with this hypothesis is the finding that Type I
heterozygotes, with presumably 50% of SLC3A1 function,
excrete cystine in the normal range. On the other hand,
mutations in the cystinuria gene at 19q13.1, encoding Type
III and Type II phenotypes, are associated with moderate
cystinuria in the heterozygous state.
Although we identified 15/16 mutations in the Type I/I
probands (a 94% detection rate), we only identified 1/9
mutations (11% detection rate) in the Type I allele of the
Type I/III probands. It is unlikely that our detection
strategy, which covered the entire coding sequence and
intronic boundaries, would miss such a high percentage of
mutations in SLC3A1, particularly since our detection rate
was so high among Type I/I probands, and all patients were
Fig. 4. Expression analysis of missense mutations in Xenopus oocytes.
The graph depicts the mean and SD for cystine uptake in 10 oocytes for
each construct. (A) Uptake was measured 24 hours after injection for
wild-type D2H/SLC3A1 (D2H-wt) and for four missense mutations
(T216M, S217R, R270L, and I618M). Uptake was significantly decreased
for all mutant constructs except the I618M substitution. (B) Uptake was
measured six hours after injection for the wild-type (D2H-wt) and the
S217R constructs. The S217R construct had significantly decreased uptake
compared to the control.
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analyzed together. A plausible explanation is that the
mutations in these Type I alleles are caused by defects in a
gene other than SLC3A1. The most likely candidate at the
present time is the Type III (or Type II) locus, which has
been linked to chromosome 19q; this gene could encode
the transporter subunit that is thought to be activated by
the SLC3A1 product [25]. These mutations might not result
in abnormal cystine excretion in the heterozygous state if
the mutations were mild. The relatively high incidence of
these patients in our population may reflect the fact that
our newborn screening program identifies all patients with
cystinuria whether or not they have formed kidney stones.
It is critical, therefore, to distinguish between the phe-
notypic and genotypic classification for cystinuria. One
classic form of cystinuria may be defined in which children
of two silent carriers have high levels of cystine excretion
attributable to two mutations of the SLC3A1 gene. In
children with a mixed cystinuria phenotype, the frequency
of SLC3A1 mutations is low and the molecular genetics
appears to be more complicated. A clear understanding of
these subtypes will require the isolation of other cystinuria
genes.
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